• Diabetes/Endocrine/Metabolic Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • PMU139 VALIDITY OF THE SLOVENIAN VERSION OF THE CARERQOL-7D QUESTIONNAIRE AMONG INFORMAL CAREGIVERS IN THE SLOVENIAN GENERAL POPULATION

    Nov 1, 2019, 00:00

  • PMU87 REVIEW OF ORPHAN TREATMENTS ASSESSED BY NICE AND THE SMC IN THE UK.

    Nov 1, 2019, 00:00

  • PNS371 EVALUATING QUALITY OF PRIMARY HEALTH CARE (PHC) SERVICES FROM THE PATIENTS' PERSPECTIVE IN GREECE

    Nov 1, 2019, 00:00

  • PDB41 HOW ECONOMIC ANALYSIS INCREASE AWARENESS ON CLINICAL SERVICE, A CASE OF DIABETES MELLITUS AT A TEACHING HOSPITAL IN MYANMAR

    Nov 1, 2019, 00:00

  • PDB43 COST COMPARISON OF GLICAZIDE MODIFIED-RELEASE AND GENERIC GLICLAZIDE IN PREVENTING END STAGE RENAL DISEASE IN TYPE 2 DIABETES MELLITUS IN THE PUBLIC SECTOR OF MALAYSIA

    Nov 1, 2019, 00:00

  • PCV51 COST-EFFECTIVENESS OF RIVAROXABAN IN THE TREATMENT OF PATIENTS WITH CHRONIC CAD OR PAD IN THE UK

    Nov 1, 2019, 00:00

  • PRS71 NEW METHODS FOR ANALYZING CLINICAL AND COST OUTCOMES IN ASTHMA WITH INTERACTIVE VISUAL ANALYTICS

    Nov 1, 2019, 00:00

  • PBI65 ASSESSMENT OF WILLINGNESS TO PAY IN A RAPIDLY INCREASING BIOLOGICS MARKET FOR RESPIRATORY DISEASES

    Nov 1, 2019, 00:00

  • PCN96 COST-EFFECTIVENESS OF TREATMENT SEQUENCES FOR BRAF WILD-TYPE METASTATIC MELANOMA IN REAL LIFE IN FRANCE

    Nov 1, 2019, 00:00

  • PMU53 THE INCENTIVE FINANCIAL FRAMEWORK REGARDING FRENCH HOSPITAL PRESCRIPTION OF BIOSIMILAR MEDICINES WHEN DELIVERED IN RETAIL PHARMACY: IMPACT ANALYSIS OF ARTICLE 51 EXPERIMENTATION FOR 2018

    Nov 1, 2019, 00:00

  • PUK39 URINARY TRACT INFECTIONS (UTIS) AFTER UROGENITAL PROCEDURES AND RELATED OUTCOMES AND COSTS: ANALYSIS OF DATA FROM THE NATIONAL HOSPITAL INFORMATION SYSTEM

    Nov 1, 2019, 00:00

  • PRO105 A REVIEW OF SIX YEARS OF THE NICE HIGHLY SPECIALISED TECHNOLOGY (HST) PROGRAMME

    Nov 1, 2019, 00:00

  • PCN16 ASSESSMENT OF THE QUALITY OF LIFE, PHYSICAL ACTIVITY, DEPRESSION AND ANXIETY OF PATIENTS UNDER ONCOLOGY CARE

    Nov 1, 2019, 00:00

  • PMD37 EVOLUTION OF UNION EUROPEAN MEDICAL DEVICE REGULATION: PERSPECTIVE WITH THE CLINICAL EVALUATION OF DUAL MOBILITY ACETABULAR CUPS BY THE FRENCH NATIONAL HEALTH TECHNOLOGY ASSESSMENT AGENCY

    Nov 1, 2019, 00:00

  • PIT2 PATTERNS OF OPIOID USE FOLLOWING FRACTURE BASED ON TIME BETWEEN PRESCRIPTION ORDER AND PATIENT FILL

    Nov 1, 2019, 00:00

  • PCN400 ONCOLOGY-RELATED HTA DECISIONS IN GERMANY, FRANCE, SPAIN AND THE UK: ASSESSMENT OF SIMILARITIES AND DIFFERENCES

    Nov 1, 2019, 00:00

  • PDB35 COST-EFFECTIVENESS OF GLICLAZIDE MR-BASED INTENSIVE GLUCOSE CONTROL VERSUS STANDARD GLUCOSE CONTROL IN TYPE 2 DIABETES MELLITUS. AN ECONOMIC ANALYSIS IN VIETNAM OF THE ADVANCE TRIAL

    Nov 1, 2019, 00:00

  • PIN49 BURDEN OF S. AUREUS, E. COLI, K. PNEUMONIAE ASSOTIATED INFECTIONS IN RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PCV14 COMPARATIVE EFFECTIVENESS AND SAFETY OF ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: A PROPENSITY SCORE-MATCHED COHORT STUDY

    Nov 1, 2019, 00:00

  • PCN419 THE USE OF INDIVIDUAL PATIENT-LEVEL DATA (IPD) TO CONDUCT INDIRECT TREATMENT COMPARISONS (ITCS) IN SUBMISSIONS TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    Nov 1, 2019, 00:00

  • PNS370 METHODS AND CONSIDERATIONS FOR THE DEVELOPMENT, CONTENT VALIDITY TESTING, AND EVALUATION OF PATIENT EDUCATION TOOLS (PETS)

    Nov 1, 2019, 00:00

  • PNS138 TRANSNATIONAL COLLABORATIONS AMONG DRUG REGULATORY AGENCIES: TRENDS AND FUTURE PERSPECTIVES

    Nov 1, 2019, 00:00

  • PCN176 COST-EFFECTIVENESS OF SECOND-LINE NILOTINIB VERSUS DASATINIB FOR THE TREATMENT OF PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA-CHRONIC PHASE (PH+ CML-CP) IN ITALY

    Nov 1, 2019, 00:00

  • PRS69 TREATMENT OF COPD PATIENTS IN GERMANY AND THE NEED FOR THERAPY ESCALATION: A CLAIMS DATA ANALYSIS

    Nov 1, 2019, 00:00

  • PCN139 BUDGET IMPACT ANALYSIS OF NILOTINIB AS FIRST LINE TREATMENT OF NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) WITH HIGH RISK SOKAL SCORE IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    Nov 1, 2019, 00:00

  • PND51 PRODUCTIVITY LOSS IN NHS HOSPITALS DUE TO DIFFICULT-TO-TREAT MIGRAINE

    Nov 1, 2019, 00:00

  • PCN18 CLINICAL BENEFITS OF REHABILITATION IN PATIENTS WITH ADVANCED CANCER IN KOREA

    Nov 1, 2019, 00:00

  • PCN414 INCLUSION OF SUBSEQUENT TREATMENTS WITH CURATIVE INTENT IN ADVANCED HEPATOCELLULAR CARCINOMA (AHCC) PARTITIONED SURVIVAL MODELS

    Nov 1, 2019, 00:00

  • PCV17 HEALTHCARE UTILIZATION PRIOR TO AN INITIAL DIAGNOSIS OF PAROXYSMAL SUPRVENTRICULAR TACHYCARDIA IN A LARGE HEALTHCARE SYSTEM

    Nov 1, 2019, 00:00

  • PCN465 VIRTUAL COMMUNITY ENGAGEMENT AMONG WOMEN RECEIVING PALBOCICLIB FOR HR+/ HER2- METASTATIC BREAST CANCER: DATA FROM THE MADELINE STUDY

    Nov 1, 2019, 00:00

  • PDB9 SERUM GGT AND HSCRP: EARLY PREDICTORS OF OXIDATIVE STRESS AND INFLAMMATION IN TYPE 2 DIABETES MELLITUS PATIENTS WITH GOOD AND POOR GLYCEMIC CONTORL

    Nov 1, 2019, 00:00

  • PND80 HEALTHCARE UTILISATION AND PERCEIVED HEALTH NEEDS OF MULTIPLE SCLEROSIS PATIENTS IN GREECE: EVIDENCE FROM A QUALITATIVE STUDY

    Nov 1, 2019, 00:00

  • PCN164 COST-EFFECTIVENESS OF DACOMITINIB VS. GEFITINIB AS FIRST-LINE TREATMENT FOR EGFR MUTATION POSITIVE ADVANCED NON-SMALL-CELL LUNG CANCER IN CHINA

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PND130 TREATMENT PATTERNS, HEALTH RESOURCES CONSUMPTION AND COSTS OF PATIENTS WITH MIGRAINE IN AN ITALIAN REAL-WORLD SETTING

    Nov 1, 2019, 00:00

  • PNS231 MANAGED ENTRY AGREEMENTS FOR PRESCRIPTION DRUGS IN SWEDEN

    Nov 1, 2019, 00:00

  • PMH2 BREXANOLONE INJECTION IN POSTPARTUM DEPRESSION: SUSTAINED REMISSION, SUSTAINED RESPONSE, AND NUMBER NEEDED TO TREAT

    Nov 1, 2019, 00:00

  • PMU130 REPRESENTATIVENESS OF THE NATIONAL HEALTH AND WELLNESS SURVEY IN EUROPE: CURRENT EPIDEMIOLOGY ACROSS MULTIPLE DISEASES

    Nov 1, 2019, 00:00

  • PIN2 EFFECTIVENESS AND SAFETY OF DIRECT-ACTING ANTIVIRALS FOR HEPATITIS C VIRUS INFECTED PATIENTS AFTER LIVER TRANSPLANTATION. RESULTS IN REAL CLINICAL PRACTICE.

    Nov 1, 2019, 00:00

  • PCN206 NETUPITANT AND PALONOSETRON (NEPA), IS A COST-EFFECTIVE INTERVENTION FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN SINGAPORE

    Nov 1, 2019, 00:00

  • PSY17 REAL-WORLD COST DIFFERENCE IN PATIENTS WITH PSORIASIS NEWLY INITIATING APREMILAST VS. BIOLOGIC TREATMENT AFTER CONVENTIONAL SYSTEMIC THERAPY: A RETROSPECTIVE ANALYSIS OF GERMAN SICKNESS FUND DATA

    Nov 1, 2019, 00:00

  • PCN185 PERTUZUMAB RISK SHARING AGREEMENT IN THE PORTUGUESE NHS: A 4-YEAR EXPERIENCE

    Nov 1, 2019, 00:00

  • PCN306 THE MODEL OF OUTCOMES-BASED RISK SHARING AGREEMENTS APPLIED TO TARGETED DRUGS IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PND55 ECONOMIC EVALUATION OF ENDOSCOPIC THIRD VENTRICULOSTOMY COMPARED TO SHUNTING IN PEDIATRIC PATIENTS WITH HYDROCEPHALUS IN UZBEKISTAN

    Nov 1, 2019, 00:00

  • Projected Cost-Effectiveness for 2 Gene-Drug Pairs Using a Multigene Panel for Patients Undergoing Percutaneous Coronary Intervention

    Nov 1, 2019, 00:00

  • PCN356 ARE CANCER DRUGS ASSOCIATED WITH A COMPANION DIAGNOSTIC TEST TAKING LONGER TO BE REIMBURSED IN AUSTRALIA?

    Nov 1, 2019, 00:00

  • PDG2 METHYLNALTREXONE FOR OPIOID-INDUCED CONSTIPATION IN PATIENTS RECEIVING PALLIATIVE CARE: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PDB82 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): COUNTRY-SPECIFIC BASELINE CHARACTERISTICS

    Nov 1, 2019, 00:00

  • PCN20 ACCURATE PREDICTIONS OF LIFE YEAR GAINS FOR IMMUNO-ONCOLOGY THERAPIES IN THE LONG TERM? AN ANALYSIS BASED ON PUBLISHED CHECKMATE 057 NIVOLUMAB DATA

    Nov 1, 2019, 00:00

  • CP2 DO SOCIAL VALUES AND INSTITUTIONAL CONTEXT IMPACT THE USE OF ECONOMIC EVALUATION IN PRIORITY SETTING: EMPIRICAL EVIDENCE FROM OECD COUNTRIES

    Nov 1, 2019, 00:00

  • PNS343 THE COMPLETENESS OF CLINICALTRIALS.GOV. - WHAT IS THE RATE OF PUBLISHED CLINICAL TRIALS REGISTERED ON THE WEBSITE?

    Nov 1, 2019, 00:00

  • PCN355 DO PAYER AND PRESCRIBER ENDPOINT PREFERENCES ALIGN?: IMMUNE CHECKPOINT INHIBITORS IN NON-SMALL CELL LUNG CANCER

    Nov 1, 2019, 00:00

  • PRO56 ECONOMIC IMPACT OF THE INTRODUCTION OF RFVIII-SINGLECHAIN (AFSTYLA®) FOR THE TREATMENT OF HEMOPHILIA A IN ITALY

    Nov 1, 2019, 00:00

  • PDG104 DECREASING NUMBER OF PRESCRIPTIONS AFTER THEY BECAME MANDATORY AND THEIR VALIDITY PERIOD WAS EXTENDED TO TWO YEARS: CASE FINLAND SINCE 2017

    Nov 1, 2019, 00:00

  • PCN285 THERAPEUTIC BENEFIT OF ORPHAN DRUGS IN ONCOLOGY: EVIDENCE AT THE POINT OF EUROPEAN MARKETING AUTHORISATION

    Nov 1, 2019, 00:00

  • PCV16 MULTIPLE STATISTICAL APPROACHES IN COMPARATIVE EFFECTIVENESS RESEARCH (CER): THE EXAMPLE OF NAXOS, A LARGE FRENCH CER

    Nov 1, 2019, 00:00

  • Personalized Process of Care

    Nov 1, 2019, 00:00

  • PCN496 BURDEN OF ACUTE MYELOID LEUKEMIA AMONG NEWLY DIAGNOSED PATIENTS IN SOUTH KOREA: RETROSPECTIVE EMR DATABASE ANALYSIS

    Nov 1, 2019, 00:00

  • PIN64 COST OF HEPATITIS C VIRUS ERADICATION: ECONOMIC MODEL CONCEPT

    Nov 1, 2019, 00:00

  • Drugs Generics - Organizational Practices

    Nov 1, 2019, 00:00

  • PND47 CLADRIBINE TABLET, AS A DOMINANT COMPARATOR TO NATALIZUMAB IN HIGH-DISEASE ACTIVITY RELAPSING MULTIPLE SCLEROSIS PATIENTS, IN THE CONTEXT OF A DEVELOPING COUNTRY

    Nov 1, 2019, 00:00

  • PNS235 ASSESSMENT OF DIGITAL HEALTH TECHNOLOGIES - COMPARISON OF EVIDENCE FRAMEWORKS OF NICE AND HAS

    Nov 1, 2019, 00:00

  • PDG78 IMPACT OF FIRST RELATIVE EFFECTIVENESS ASSESSMENTS (REAS) FROM EUNETHTA ON DRUG HTA ASSESSMENTS BY HAS, IQWIG AND NICE

    Nov 1, 2019, 00:00

  • PNS244 PAN-EU CLINICAL HTA – A NON-UNIFORM IMPACT?

    Nov 1, 2019, 00:00

  • PND43 BUDGET IMPACT OF THE INTRODUCTION OF ALEMTUZUMAB IN NORWAY; A REAL WORLD EVIDENCE ANALYSIS USING DATA FROM THE NORWEGIAN PATIENT REGISTRY, THE NORWEGIAN PRESCRIPTION DATABASE, AND IMS SALES DATA

    Nov 1, 2019, 00:00

  • PCV100 THE RELATIONSHIP BETWEEN PROCEDURAL VOLUME AND POSTOPERATIVE MORTALITY FOR PERCUTANEOUS CORONARY INTERVENTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2019, 00:00

  • PCN258 APPLYING BIG DATA ANALYTICS TO DEVELOP PREDICTIVE MODELS FOR ESTIMATING HER2+ BC INCIDENCE AND PREVALENCE IN BRAZIL

    Nov 1, 2019, 00:00

  • PNS148 VALUE-BASED PROCUREMENT: UNDERSTANDING HOW PAYERS APPROACH AND IMPLEMENT CONTRACTING AND PROCUREMENT OF NOVEL TREATMENTS BASED ON THEIR VALUE

    Nov 1, 2019, 00:00

  • PNS288 ANALYSIS OF RECENT TRENDS IN E-HEALTH SOLUTIONS DEVELOPED BY PHARMACEUTICAL AND BIOTECH COMPANIES

    Nov 1, 2019, 00:00

  • PCN218 COST-EFFECTIVENESS OF APALUTAMIDE + ADT VERSUS ENZALUTAMIDE + ADT IN NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER IN GREECE

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Medical Technologies

    Nov 1, 2019, 00:00

  • PMU105 ACCEPTANCE OF EVIDENCE TRANSFER FROM ADULTS TO CHILDREN IN THE CONTEXT OF BENEFIT ASSESSMENT IN GERMANY, FRANCE, AND UK

    Nov 1, 2019, 00:00

  • Medical Devices - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PDB3 HETEROGENEITY IN RENAL COMPOSITE ENDPOINTS IN CARDIOVASCULAR OUTCOMES TRIALS IN TYPE 2 DIABETES (T2D)

    Nov 1, 2019, 00:00

  • PGI58 A STUDY OF LONG TERM HOSPITALIZATION COSTS IN PATIENTS WITH ULCERATIVE COLITIS USING GERMAN CLAIMS DATA

    Nov 1, 2019, 00:00

  • PCN149 COST-EFFECTIVENESS ANALYSIS OF DABRAFENIB+TRAMETINIB VERSUS WATCHFUL WAITING IN THE ADJUVANT TREATMENT OF PATIENTS WITH RESECTED BRAF V600 POSITIVE STAGE III MELANOMA : A FRENCH PERSPECTIVE

    Nov 1, 2019, 00:00

  • PIH28 A REAL WORLD ANALYSIS OF PREVALENCE OF SYMPTOMS AND HEALTHCARE UTILIZATION IN WOMEN WITH MENOPAUSE

    Nov 1, 2019, 00:00

  • PDG98 A DISPROPORTIONALITY ANALYSIS OF SPONTANEOUS ADVERSE EVENT REPORTS FOR OSTEONECROSIS OF JAW ATTRIBUTED TO AROMATASE INHIBITORS IN FDA ADVERSE EVENTS REPORTING SYSTEM

    Nov 1, 2019, 00:00

  • PNS278 A REVIEW OF HEALTH TECHNOLOGY ASSESSMENT GUIDELINES ON THE APPROVAL OF BIOSIMILARS

    Nov 1, 2019, 00:00

  • PCN371 A REVIEW OF SWEDISH HEALTH TECHNOLOGY ASSESSMENTS BASED ON INDIRECT COMPARISONS OF HOSPITAL DRUGS IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PCN444 DYNAMIC SURVIVAL MODELS FOR INCORPORATING EXTERNAL EVIDENCE WHEN EXTRAPOLATING OVERALL SURVIVAL: A CASE STUDY.

    Nov 1, 2019, 00:00

  • PCN357 PREDICTOR OF A POSITIVE RECOMMENDATION IN NICE ONCOLOGY APPRAISALS

    Nov 1, 2019, 00:00

  • PMU140 A COMPREHENSIVE CATALOGUE OF EQ-5D SCORES IN CHRONIC DISEASE: RESULTS OF A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PCV61 COST EFFECTIVENESS OF RIVAROXABAN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION PATIENTS FOR TTR AND CHADS2 SCORE IN TURKEY

    Nov 1, 2019, 00:00

  • PND102 BURDEN OF COMORBID DEPRESSION AND ANXIETY ON MIGRAINE-SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN ADULT MIGRAINE PATIENTS IN THE UNITED STATES

    Nov 1, 2019, 00:00

  • PCN37 THE BENEFIT OF ADJUVANT CHEMOTHERAPY FOR PATIENTS AGED 75 OR OLDER WITH STAGE III COLON CANCER

    Nov 1, 2019, 00:00

  • PDB125 PREDICTING NASH PATIENTS USING INNOVATIVE MACHINE LEARNING TECHNIQUES

    Nov 1, 2019, 00:00

  • PCN324 PRELIMINARY EVIDENCE SUGGESTS THAT WE MOVE TOWARDS THE USE OF LIQUID BIOPSIES TO PREDICT RESPONSE TO TKI INHIBITORS: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PNS145 THE MALTESE EXCEPTIONAL MEDICINAL TREATMENT ROUTE: A BYPASS TO HEALTHCARE?

    Nov 1, 2019, 00:00

  • PCN509 REAL-WORLD EVIDENCE ON PATIENTS WITH RELAPSED/REFRACTORY FLT3 MUTATION-POSITIVE ACUTE MYELOID LEUKEMIA IN ITALY

    Nov 1, 2019, 00:00

  • PRO107 UNDERSTANDING THE PRICING AND REIMBURSEMENT (PR) LANDSCAPE OF ORPHAN DRUGS IN EMERGING MARKETS

    Nov 1, 2019, 00:00

  • PCN338 KEY DRIVERS OF HEALTH TECHNOLOGY ASSESSMENT DECISIONS FOR RELAPSED-REFRACTORY MULTIPLE MYELOMA TREATMENTS; A COUNTRY COMPARISON.

    Nov 1, 2019, 00:00

  • PDB49 THE RELATIONSHIP BETWEEN HBA1C REDUCTION AND COSTS: A COHORT STUDY OF PATIENTS WITH TYPE 2 DIABETES

    Nov 1, 2019, 00:00

  • PIN153 HEALTH OUTCOMES AND HEALTH SYSTEM COSTS ASSOCIATED WITH SEPSIS: A POPULATION-BASED, RETROSPECTIVE COHORT STUDY

    Nov 1, 2019, 00:00

  • PNS18 CAN REFLECTIVE MCDA CONTRIBUTE TO ACHIEVING EMA'S STRATEGIC OBJECTIVES FOR REGULATORY SCIENCE TO 2025? WHEN THE BOTTOM UP APPROACH CAN BE THE WAY TO GO: INSIGHTS FROM SPANISH EXPERIENCE

    Nov 1, 2019, 00:00

  • PSU40 PREDICTORS OF HEALTH-RELATED QUALITY OF LIFE AFTER TOTAL JOINT REPLACEMENT: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN203 HEALTH-CARE RESOURCE USE AND COSTS IN AML-PATIENTS UNDERGOING STEM CELL TRANSPLANTATION

    Nov 1, 2019, 00:00

  • PRS73 POLLEN EXPOSURE AND ASTHMA-RELATED HEALTHCARE RESOURCE UTILIZATION IN CHILDREN WITH ASTHMA: AN ANALYSIS OF PATIENT-LEVEL CLAIMS AND LINKED WEATHER DATA

    Nov 1, 2019, 00:00

  • PCN422 BAYESIAN MODEL AVERAGING FOR EXTRAPOLATING SURVIVAL: A PAN-TUMOR PERSPECTIVE ON NIVOLUMAB AND IPILIMUMAB

    Nov 1, 2019, 00:00

  • PAM15 PHOTOGRAPHIC FOOD DIARIES FOR NUTRITIONAL RESEARCH WITH CHILDREN AND HARD-TO-REACH POPULATIONS: A CASE STUDY EXPLORATION OF A NOVEL ASSESSMENT TOOL

    Nov 1, 2019, 00:00

  • PNS58 ANALYSIS OF FINANCIAL STATUS AND DETERMINANTS WITH ALTMAN'S Z-SCORE MODEL: A PANEL DATA INVESTIGATION FROM TRADITIONAL CHINESE MEDICINE LISTED COMPANIES IN CHINA

    Nov 1, 2019, 00:00

  • PND67 IDENTIFICATION AND CHARACTERIZATION OF HIGH DISEASE ACTIVITY RELAPSING REMITTING MULTIPLE SCLEROSIS ADULT PATIENTS BASED ON THE SNIIRAM DATABASE

    Nov 1, 2019, 00:00

  • PCN301 PATIENT ACCESS TO PERSONALIZED ONCOLOGY MEDICINES IN TURKEY

    Nov 1, 2019, 00:00

  • PIN43 LIFECYCLE-MODEL-BASED ECONOMIC EVALUATION OF INFANT MENINGITIS B VACCINATION IN THE UK

    Nov 1, 2019, 00:00

  • PND125 PREGABALIN PRESCRIBING IN PRIVATE HEALTHCARE SETTINGS IN SOUTH AFRICA WITH SPECIFIC FOCUS ON DOSAGES

    Nov 1, 2019, 00:00

  • PCN313 REAL-WORLD DATA ON THE USE OF ANTINEOPLASTIC PHARMACOTHERAPY REGIMENS AMONG PATIENTS WITH SKIN MELANOMA IN RUSSIA

    Nov 1, 2019, 00:00

  • PCN320 ADMINISTRATIVE OVERSIGHT SHORTENS WAIT-TIME TO BEGIN RADIOTHERAPY IN THE PUBLIC SYSTEM

    Nov 1, 2019, 00:00

  • PCN234 COST-EFFECTIVENESS ANALYSIS OF HOME-BASED PALLIATIVE CARE FOR END-STAGE CANCER PATIENTS

    Nov 1, 2019, 00:00

  • PSU18 THE COST-EFFECTIVENESS OF ENOXAPARIN IN THE PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING MAJOR SURGERY IN EGYPT

    Nov 1, 2019, 00:00

  • PGI24 IBD INTEGRATED MODEL OF CARE LEADS TO COST SAVINGS: A BUDGET IMPACT MODEL FOR A RUSSIAN REGION

    Nov 1, 2019, 00:00

  • PGI31 SENSITIVITY OF INCREASING BODY WEIGHT IN PATIENTS WITH COLLITIS ULCEROSA TO TOTAL COST OF TREATMENT

    Nov 1, 2019, 00:00

  • PCN411 HOW ARE SINGLE-ARM TRIALS PERCEIVED IN HEATH TECHNOLOGY ASSESSMENTS FOR CHRONIC LEUKAEMIA ACROSS THE EU5, AUSTRALIA AND CANADA?

    Nov 1, 2019, 00:00

  • PCN85 COST-EFFECTIVENESS OF TISAGENLECLEUCEL IN PAEDIATRIC AND YOUNG ADULT RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBASTIC LEUKAEMIA, FROM A GREEK SOCIAL SECURITY SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • PNS215 IMPACT OF CONDITIONAL MARKETING AUTHORISATION AND ACCELERATED ASSESSMENT ON HEALTH TECHNOLOGY ASSESSMENT (HTA) OUTCOMES

    Nov 1, 2019, 00:00

  • PIN77 EFFICACY MISAPPLICATION IN VACCINE MODELLING

    Nov 1, 2019, 00:00

  • PNS396 VALUING HEALTH RELATED QUALITY OF LIFE IN MOROCCO: AN EQ-5D-3L VALUE SET

    Nov 1, 2019, 00:00

  • Pneumococcal Disease: A Systematic Review of Health Utilities, Resource Use, Costs, and Economic Evaluations of Interventions [Editor's Choice]

    Nov 1, 2019, 00:00

  • PCN243 COST-MINIMIZATION OF VENETOCLAX WITH RITUXIMAB VERSUS IBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    Nov 1, 2019, 00:00

  • Medical Devices - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PNS359 INTERNATIONAL OBSERVATIONAL STUDIES: THE INCREASED NEED FOR A COMMON EUROPEAN REGULATION

    Nov 1, 2019, 00:00

  • PDG107 DRUG SURVIVAL OF BIOLOGICAL THERAPIES FOR ANKYLOSING SPONDYLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF REAL-WORLD EVIDENCE

    Nov 1, 2019, 00:00

  • PCN366 TREATMENT LANDSCAPE AND KEY DRIVERS FOR HTA DECISIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITHOUT EGFR OR ALK ALTERATIONS

    Nov 1, 2019, 00:00

  • PND101 AN UPDATE OF A SYSTEMATIC REVIEW: ATTRIBUTE BASED STATED PREFERENCE STUDIES IN MULTIPLE SCLEROSIS PATIENTS

    Nov 1, 2019, 00:00

  • PCN55 NETWORK META-ANALYSIS COMPARING PALBOCICLIB PLUS FULVESTRANT WITH EVEROLIMUS PLUS EXEMESTANE FOR HR+/HER2- ADVANCED BREAST CANCER THAT HAS BECOME RESISTANT TO PREVIOUS ENDOCRINE THERAPY

    Nov 1, 2019, 00:00

  • PCV57 STUDY ON THE ATTRIBUTABLE COSTS OF VENOUS THROMBOEMBOLISM AND BLEEDINGS IN DENMARK. COMPARISON OF THE DIFFERENCE-IN-DIFFERENCE AND THE DIFFERENCE-IN-ACTUAL-COSTS METHODS

    Nov 1, 2019, 00:00

  • PNS213 NICE FAST TRACK APPRAISALS: A DESCRIPTIVE OVERVIEW

    Nov 1, 2019, 00:00

  • PCN239 MEDICAL COST OF RITUXIMAB-CONTAINING THERAPY IN PATIENTS WITH FOLLICULAR LYMPHOMA IN JAPAN: R-B IS LESS EXPENSIVE THAN R-CHOP

    Nov 1, 2019, 00:00

  • PCN503 USE OF HEALTH ECONOMICS AND OUTCOMES RESEARCH TO INFORM TREATMENT DECISIONS AMONG US ONCOLOGISTS

    Nov 1, 2019, 00:00

  • PMS51 TRAJECTORIES OF FOLLOW-UP COMPLIANCE AND THEIR PREDICTORS IN A FRACTURE LIAISON SERVICE

    Nov 1, 2019, 00:00

  • PCN35 SURVEILLANCE FOR PATIENTS WITH LI-FRAUMENI SYNDROME

    Nov 1, 2019, 00:00

  • PCN327 KEY INTERVALS IN THE PATIENT JOURNEY OF MEN WITH PROSTATE CANCER: EVIDENCE FROM GREECE

    Nov 1, 2019, 00:00

  • PCN144 ECONOMIC EVALUATIONS OF CANCER INTERVENTIONS IN SPAIN: LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • Mental Health - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PMS20 COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN ANKYLOSING SPONDYLITIS IN BIOLOGIC-EXPERIENCED PATIENTS FROM THE PORTUGUESE PERSPECTIVE

    Nov 1, 2019, 00:00

  • PUK30 COMPARING SOFTWARE FOR PATIENT-LEVEL SIMULATION: REPLICATING A MODEL OF HYPERPHOSPHATAEMIA IN CHRONIC KIDNEY DISEASE

    Nov 1, 2019, 00:00

  • PNS392 THE ROLE OF PATIENTS IN THE UPTAKE OF PHARMACEUTICAL PRODUCTS BY PATIENTS AS PERCEIVED BY PROFESSIONALS

    Nov 1, 2019, 00:00

  • PCN255 ESTIMATION OF THE POTENTIAL IMPACT OF THE FRENCH CRC SCREENING PROGRAM BASED ON REAL-WORLD PARTICIPATION RATES

    Nov 1, 2019, 00:00

  • PCN114 ASSESSMENT OF THE SURVIVAL BENEFIT AND COST IMPACT OF NEW TREATMENTS FOR KEY ANSCLC BIOMARKERS USING THE ITEN MODEL

    Nov 1, 2019, 00:00

  • PCV66 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF ARTERIAL EMBOLISM AND THROMBOSIS IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PND65 FILLING THE GAP IN MS; UNIQUE IDENTIFICATION OF PREVALANCE TREATMENT OF SPMS PATIENTS IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PCN247 COST-EFFECTIVENESS OF PERTUZUMAB PLUS TRASTUZUMAB VS TRASTUZUMAB IN NEOADJUVANT SETTING BASED ON THE NEOSPHERE TRIAL IN TURKEY

    Nov 1, 2019, 00:00

  • PNS6 SYSTEMATIC LITERATIVE REVIEW AND QUALITATIVE ANALYSIS ASSESSING EFFICACY AND SAFETY OF INTERVENTIONS IN ACTINIC KERATOSIS

    Nov 1, 2019, 00:00

  • PCN248 COST-UTILITY ANALYSIS OF FIRST-LINE THERAPY FOR ADVANCED AND METASTATIC PANCREATIC CANCER IN JAPAN.

    Nov 1, 2019, 00:00

  • PSY45 PATIENT-REPORTED OUTCOMES USED IN CLINICAL TRIALS OF SYSTEMIC LUPUS ERYTHEMATOSUS: A REVIEW OF SUITABILITY FOR FDA LABELLING CLAIMS

    Nov 1, 2019, 00:00

  • Individual's Health - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PGI30 THE MEDICAL COSTS OF INFLAMMATORY BOWEL DISEASE IN RUSSIA FROM A PUBLIC PAYER PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN474 MAPPING PATIENT INVOLVEMENT IN NICE APPRAISALS OF ONCOLOGY PRODUCTS

    Nov 1, 2019, 00:00

  • PNS87 IMPACT OF SELF SUSTAINABLE SYSTEM FOR SAFE DRUG DISPOSAL: A FOLLOW UP STUDY

    Nov 1, 2019, 00:00

  • PCN373 RECENT COST PER QALY TRENDS OF NON-HAEMATOLOGICAL CANCERS ASSESSMENT AT NICE

    Nov 1, 2019, 00:00

  • PCN460 SYSTEMATIC LITERATURE REVIEW FOR UTILITY DATA IN ACUTE MYELOID LEUKEMIA

    Nov 1, 2019, 00:00

  • PUK3 TREATMENT EFFECTS IN SECONDARY HYPERPARATHYROIDISM IN NON-DIALYSIS CHRONIC KIDNEY DISEASE: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PNS63 WILLINGNESS TO PAY FOR HEALTH INSURANCE USING THE CONTINGENT VALUATION METHOD: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PBI37 BIOSIMILAR INTERCHANGEABILITY, SUBSTITUTION AND SWITCHING: AN OVERVIEW OF 5 EUROPEAN MEMBER STATES AND THE UNITED STATES

    Nov 1, 2019, 00:00

  • PBI9 SYSTEMATIC LITERATURE REVIEW OF NMAS AND POPULATION ADJUSTED INDIRECT COMPARISONS OF BIOLOGICAL TREATMENTS IN MODERATE-TO-SEVERE PSORIASIS

    Nov 1, 2019, 00:00

  • PNS368 THE EVOLVING ROLE OF PATIENT ADVOCACY IN DRUG APPRAISAL AND COMMISSIONING: PERSPECTIVES FROM ENGLAND

    Nov 1, 2019, 00:00

  • PSY49 THE JOURNEY OF THALASSAEMIA PATIENT IN SEEKING TREATMENT IN MALAYSIAN HEALTHCARE

    Nov 1, 2019, 00:00

  • PMH32 THE ECONOMIC BURDEN OF ALCOHOL CONSUMPTION IN THE CZECH REPUBLIC

    Nov 1, 2019, 00:00

  • PCN254 CHARACTERISING INDIVIDUALS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER USING ROUTINE LINKED HEALTH DATASETS: A FEASIBILITY STUDY

    Nov 1, 2019, 00:00

  • PCN146 VALIDATION OF PREDICTED SURVIVAL ESTIMATES FROM PREVIOUS DATA CUTS OF THE PHASE III CHECKMATE 025 STUDY IN ADVANCED RENAL CELL CARCINOMA

    Nov 1, 2019, 00:00

  • PND53 ECONOMIC EVALUATION OF CLADRIBINE TABLETS IN RELAPSING MULTIPLE SCLEROSIS (RMS) PATIENTS WITH HIGH DISEASE ACTIVITY (HDA) IN LEBANON

    Nov 1, 2019, 00:00

  • PRO69 EPIDEMIOLOGICAL MODEL TO SUPPORT ORPHAN DESIGNATION DECISIONS: A DICE SIMULATION STUDY

    Nov 1, 2019, 00:00

  • PCN452 COMPARING OUTCOMES OF DIFFERENT STANDARD AND NOVEL APPROACHES THAT INCORPORATE GENERAL POPULATION MORTALITY HAZARDS IN SURVIVAL EXTRAPOLATIONS

    Nov 1, 2019, 00:00

  • PRO29 COST-EFFECTIVENESS OF VORETIGENE NEPARVOVEC FOR VISION LOSS DUE TO BIALLELIC RPE65-MEDIATED INHERITED RETINAL DISEASE IN A DANISH SETTING

    Nov 1, 2019, 00:00

  • PMU40 NEWLY DIAGNOSED DEPRESSION AND DEPRESSION SEVERITY AMONG WOMEN WITH INCIDENT BREAST CANCER

    Nov 1, 2019, 00:00

  • PRS60 IMPACT OF SLEEP DISTURBANCE ON HEALTH-RELATED QUALITY OF LIFE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): WHAT DO WE KNOW SO FAR?

    Nov 1, 2019, 00:00

  • PCV145 ASSOCIATION BETWEEN NICORANDIL AND GASTROINTESTINAL ULCERS: A POPULATION-BASED STUDY

    Nov 1, 2019, 00:00

  • PCN165 A GERMAN COST ANALYSIS OF TRIPLET REGIMENS FOR RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS

    Nov 1, 2019, 00:00

  • PMU13 COST-EFFECTIVENESS ANALYSIS OF PCT-GUIDED ANTIBIOTIC STEWARDSHIP FOR HOSPITALIZED PATIENTS WITH SEPSIS OR LOWER RESPIRATORY TRACT INFECTIONS IN A US HOSPITAL

    Nov 1, 2019, 00:00

  • PCN330 A COMPARISON OF HEALTHCARE AND SOCIETAL COSTS OF HOSPITAL-BASED AND HOME-BASED SUBCUTANEOUS INJECTIONS OF TRASTUZUMAB

    Nov 1, 2019, 00:00

  • PMS47 SIZING THE PATIENT POTENTIAL FOR DISEASE MODIFYING OSTEOARTHRITIS THERAPIES IN USA AND EU MARKETS

    Nov 1, 2019, 00:00

  • PCV117 DESIGNING THE NEXT TRIAL FROM NETWORK META-ANALYSES USING SIMULATION-BASED ASSURANCE CALCULATIONS

    Nov 1, 2019, 00:00

  • PMH25 ASSOCIATION OF ADOLESCENT DEPRESSION WITH EARNINGS IN ADULTHOOD

    Nov 1, 2019, 00:00

  • PNS302 IMPROVING THE PERFORMANCE OF PATIENT-LEVEL SIMULATION MODELS USING MULTI-THREADING AND SINGLE INSTRUCTION MULTIPLE DATA (SIMD) OPERATIONS

    Nov 1, 2019, 00:00

  • PMU142 ASSESSING THE HUMAN AND ECONOMIC BURDEN OF SHORT STATURE: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PRO45 NATIONAL BURDEN OF HEMOPHILIA A IN TURKEY

    Nov 1, 2019, 00:00

  • PIN74 A NEW WAY TO INFORM DECISION-MAKER AND ENHANCE VACCINATION PROGRAMS IN COUNTRIES WITH LIMITED BUDGETS: THE CASE OF SERBIA

    Nov 1, 2019, 00:00

  • PUK2 A SYSTEMATIC REVIEW ASSESSING THE LONG-TERM EFFECTS OF MAINTAINING RAASI TREATMENT IN PATIENTS WITH CHRONIC KIDNEY DISEASE

    Nov 1, 2019, 00:00

  • PRO117 ACCESS TO ORPHAN DRUGS IN THE UNITED KINGDOM: A REVIEW OF NICE DECISIONS FROM 2017-2018

    Nov 1, 2019, 00:00

  • PDB33 COST-EFFECTIVENESS OF THE PDM-PROVALUE STUDY PROGRAM IN INSULIN-TREATED PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM THE GERMAN STATUTORY HEALTHCARE PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN486 REGULATORY SUCCESS IN LABELLING HRQOL AND SYMPTOMS FOR NSCLC THERAPIES

    Nov 1, 2019, 00:00

  • PNS170 CHEAP OR TIMELY DRUG? PRACTICAL IMPACT OF EXTERNAL REFERENCE PRICING POLICY IN THE EUROPEAN UNION

    Nov 1, 2019, 00:00

  • PCN481 METHODOLOGICAL ASPECTS OF HEALTH-RELATED QUALITY OF LIFE MEASUREMENT IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER IN CLINICAL TRIALS: A SYSTEMATIC REVIEW.

    Nov 1, 2019, 00:00

  • PSY10 PRIMARY SJOGREN'S SYNDROME: A RETROSPECTIVE COHORT STUDY OF BURDEN OF ILLNESS IN SWEDEN

    Nov 1, 2019, 00:00

  • Cancer - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PIN6 EVALUATION OF DIRECT-ACTING ANTIVIRALS RETREATMENT IN NON-SUSTAINED VIROLOGICAL RESPONDERS

    Nov 1, 2019, 00:00

  • PBI14 COST-EFFECTIVENESS OF SECUKINUMAB VERSUS OTHER BIOLOGICS AND APREMILAST IN THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS: A SPANISH PERSPECTIVE

    Nov 1, 2019, 00:00

  • PMD24 ECONOMIC EVALUATION OF CENTRIFUGAL AND MEMBRANE THERAPEUTIC PLASMA EXCHANGE IN TAIWAN

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PCN383 COST-EFFECTIVENES ANALYSIS OF AVELUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA IN RUSSIA

    Nov 1, 2019, 00:00

  • PSU15 COST-EFFECTIVENESS OF SHOULDER ARTHROPLASTY: A PROSPECTIVE STUDY USING REAL-WORLD DATA FROM SWITZERLAND

    Nov 1, 2019, 00:00

  • PCN259 SKELETAL ADVERSE EVENTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS: EMERGING TRENDS FROM THE US FOOD AND DRUG ADMINISTRATION ADVERSE EVENT REPORTING SYSTEM

    Nov 1, 2019, 00:00

  • PRO85 THE APPRAISAL PROCESS OF HIGH COST DRUGS FOR RARE GENETIC DISEASES IN THE PUBLIC HEALTH SYSTEM IN BRAZIL

    Nov 1, 2019, 00:00

  • Adherence, Persistence and Compliance Studies

    Nov 1, 2019, 00:00

  • PND68 ASSOCIATION BETWEEN HEPATITIS C VIRUS INFECTION AND PARKINSON'S DISEASE IN PATIENTS FOLLOWED BY GENERAL PRACTITIONERS IN GERMANY

    Nov 1, 2019, 00:00

  • PIN70 COST-EFFECTIVENESS OF SEASONAL VACCINATION WITH QUADRIVALENT INFLUENZA VACCINE IN PORTUGAL

    Nov 1, 2019, 00:00

  • PMS21 PRELIMINARY RESULTS OF A COST-UTILITY ANALYSIS OF A FRACTURE LIAISON SERVICE BASED ON HEALTH SERVICES INDICATORS

    Nov 1, 2019, 00:00

  • PSY2 SYSTEMIC LUPUS ERYTHEMATOSUS: A TARGETED LITERATURE REVIEW OF ECONOMIC BURDEN WORLDWIDE

    Nov 1, 2019, 00:00

  • Sensory System Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PMU70 FACTORS INFLUENCING THE SELECTION OF PRODUCTS FOR THE ACCELERATED ACCESS COLLABORATIVE'S RAPID UPTAKE PATHWAY

    Nov 1, 2019, 00:00

  • PND66 ASSESSING THE POTENTIALLY INAPPROPRIATE USE OF ACETYLCHOLINESTERASE INHIBITORS IN ELDERLY PATIENTS WITH PARKINSON DISEASE USING KOREA NATIONAL HEALTH INSURANCE CLAIMS DATA

    Nov 1, 2019, 00:00

  • PND60 HEALTH CARE RESOURCE UTILIZATION AND DIRECT MEDICAL COSTS AMONG PATIENTS WITH INCIDENT MIGRAINE INITIATING TREATMENT - A COHORT STUDY USING THE CLINICAL PRACTICE RESEARCH DATALINK

    Nov 1, 2019, 00:00

  • Surgery - Medical Technologies

    Nov 1, 2019, 00:00

  • PMS12 PATIENTS PRESCRIBED WITH OPIOID TREATMENT IN PRIMARY CARE PRACTICES: A POPULATION-BASED STUDY IN ITALY

    Nov 1, 2019, 00:00

  • PND39 A COST-EFFECTIVENESS ANALYSIS OF PREGABALIN VS. DULOXETINE IN THE TREATMENT OF FIBROMYALGIA IN CHINA

    Nov 1, 2019, 00:00

  • PNS121 PRIVATE HEALTH INSURANCE COLLABORATION WITH PHARMACEUTICAL COMPANIES IN EGYPT

    Nov 1, 2019, 00:00

  • PGI12 COST PER RESPONDER ANALYSIS EVALUATED THROUGH CLINICAL RESPONSE AND REMISSION RATE OF ADALIMUMAB, USTEKINUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF CROHN'S DISEASE IN BIOLOGIC NAIVE PATIENTS FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM ...

    Nov 1, 2019, 00:00

  • PNS397 PATIENTS' PERCEPTION OF THE QUALITY OF CONSULTATIONS MODELLED BY PATIENT-REPORTED EXPERIENCE AND HEALTH-RELATED QUALITY OF LIFE MEASURES

    Nov 1, 2019, 00:00

  • PNS229 COMPARATIVE ANALYSIS OF TRANSPARENCY COMMITTEE OPINION CONCERNING THE ADDED MEDICAL BENEFIT OBTAINED BY DRUGS AVAILABLE THROUGH EARLY ACCESS PROGRAM VS THE OTHERS

    Nov 1, 2019, 00:00

  • PCN376 ACCESS TO ONCOLOGY THERAPIES IN RUSSIA AND VISEGRAD GROUP COUNTRIES

    Nov 1, 2019, 00:00

  • PIH29 SELF- MEDICATION: ASSESSMENT OF PRACTICES AMONG PREGNANT WOMEN

    Nov 1, 2019, 00:00

  • Mental Health - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PCN467 THE HUMANISTIC BURDEN OF MULTIPLE MYELOMA IN NEWLY DIAGNOSED PATIENTS: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PIN76 BUDGET IMPACT OF CEFTAZIDIME AVIBACTAM (CAZ-AVI) FOR COMPLICATED INTRA-ABDOMINAL INFECTION, COMPLICATED URINARY TRACT INFECTION AND HOSPITAL-ACQUIRED PNEUMONIA IN SINGAPORE

    Nov 1, 2019, 00:00

  • PCN485 PATIENT-REPORTED OUTCOMES AND THEIR RELATIONSHIP WITH CLINICAL OUTCOMES IN PATIENTS WITH FLT3-MUTATED (FLT3 MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL STUDY

    Nov 1, 2019, 00:00

  • PMS38 COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB SC IN COMPARISON WITH ANAKINRA IN SYSTEMIC IDIOPATHIC JUVENILE ARTHRITIS (SJIA) TREATMENT IN TURKEY

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Organizational Practices

    Nov 1, 2019, 00:00

  • PCN110 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF MALIGNANT MELANOMA OF SKIN IN HUNGARY: COST OF ILLNESS PILOT STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PNS266 DIFFERENT INTERPRETATION OF ADDITIONAL EVIDENCE FOR HTA BY THE COMMISSIONED HTA BODY AND THE COMMISSIONING DECISION MAKER IN GERMANY: WHENEVER IQWIG AND FEDERAL JOINT COMMITTEE DISAGREE

    Nov 1, 2019, 00:00

  • PND72 EVOLUTION OF THE CONSUMPTION OF ANTIEPILETEC DRUGS IN MOROCCO FROM 2004 TO 2016

    Nov 1, 2019, 00:00

  • PDB69 ECONOMIC BURDEN OF TYPE 2 DIABETES (T2D) IN EMERGING AND ESTABLISHED MARKETS: DATA FROM THE G15 REVIEW

    Nov 1, 2019, 00:00

  • PIN143 MEASUREMENT OF HEALTH RELATED QUALITY OF LIFE IN TUBERCULOSIS PATIENTS USING SPECIFIC AND GENERIC INSTRUMENTS

    Nov 1, 2019, 00:00

  • PCV131 EVALUATION OF PRESCRIBING TRENDS AND ASSESSMENT OF DRUG RELATED PROBLEMS IN PATIENTS WITH ACUTE CORONARY SYNDROME

    Nov 1, 2019, 00:00

  • PCN52 ABIRATERONE VERSUS ENZALUTAMIDE IN THE POST-CHEMOTHERAPY SETTING IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: POPULATION-BASED STUDY

    Nov 1, 2019, 00:00

  • PCN454 A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ELOTUZUMAB/POMALIDOMIDE/DEXAMETHASONE (EPD) VERSUS PANOBINOSTAT/BORTEZOMIB/DEXAMETHASONE (PANO-VD) AND DARATUMUMAB MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

    Nov 1, 2019, 00:00

  • PUK38 PATTERN OF TREATMENT AND HEALTHCARE COSTS OF SECONDARY HYPERPARATHYROIDISM IN DIALYSIS PATIENTS: A REAL-WORLD EVIDENCE ANALYSIS

    Nov 1, 2019, 00:00

  • PSY56 REAL-WORLD DATA FOR HAEMOPHILIA: A SYSTEMATIC APPROACH TO IDENTIFY AND ASSESS DATA SOURCES

    Nov 1, 2019, 00:00

  • PMU30 A SYSTEMATIC REVIEW OF PREVIOUSLY PUSBLISHED OR APPRAISED HEALTH ECONOMIC MODELS ESTIMATING THE SHORT- AND LONG-TERM CONSEQUENCES OF STEROID-SPARING AGENTS

    Nov 1, 2019, 00:00

  • PNS150 CONDITIONAL MARKETING AUTHORISATION FOR NOVEL TREATMENTS: A LANDSCAPE ASSESSMENT OF EXPEDITED PATHWAYS OUTSIDE US AND EU

    Nov 1, 2019, 00:00

  • PCV83 EPIDEMIOLOGY OF STABLE CORONARY ARTERY DISEASE AND OF PERIPHERAL ARTERY DISEASE IN PORTUGAL

    Nov 1, 2019, 00:00

  • PMU103 A CRITICAL REVIEW FRAMEWORK FOR THE ASSESSMENT OF EUNETHTA METHODOLOGICAL GUIDELINES TO INFORM FUTURE JOINT CLINICAL ASSESSMENTS

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PDB38 COST OF ANTI-DIABETIC MEDICATIONS AMONG TYPE II DIABETES MELLITUS PATIENTS: A CROSS-SECTIONAL STUDY IN SOUTH INDIA

    Nov 1, 2019, 00:00

  • PCN264 ESTIMATING THE BURDEN OF SALIVARY GLAND CANCER IN NORDIC COUNTRIES: A PREDICTIVE ANALYSIS USING TIME SERIES ANALYSIS METHODS

    Nov 1, 2019, 00:00

  • PBI38 INNOVATIVE ATMPS: MARKET ACCESS AND REIMBURSEMENT DECISIONS IN THE EU5: AVAILABILITY OR NOT, THAT IS THE QUESTION...

    Nov 1, 2019, 00:00

  • PCV92 ANALYSING DATA OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION ACCORDING TO PROGRESSIVITY LEVELS IN HUNGARY (COMPARISON OF 2013 AND 2018)

    Nov 1, 2019, 00:00

  • PND36 10-YEAR COST-EFFECTIVENESS ANALYSES OF FREMANEZUMAB COMPARED TO NO TREATMENT AS A PREVENTIVE TREATMENT IN CHRONIC AND EPISODIC MIGRAINE FOR PATIENTS WITH INADEQUATE RESPONSE TO PRIOR PREVENTIVE TREATMENTS

    Nov 1, 2019, 00:00

  • PDG76 IN VITRO DATA AS COMPLEMENTARY EVIDENCE SOURCE FOR THE ASSESSMENT OF ANTIBIOTICS IN THE GERMAN BENEFIT ASSESSMENT?

    Nov 1, 2019, 00:00

  • PNS130 ANALYSIS OF LENGTH OF STAY AND COST OF INPATIENT MEDICAL CARE IN RUSSIAN DRG MODEL IN 2018

    Nov 1, 2019, 00:00

  • PCN299 MINIMUM VOLUME STANDARDS IN FRENCH HOSPITALS FOR BREAST CANCER AND OVARIAN CANCER - INEQUALITIES IN ACCESS TO HOSPITAL CARE

    Nov 1, 2019, 00:00

  • PMD15 COST EFFECTIVENESS ANALYSIS OF STANDARD AND PREMIUM INTRAOCULAR LENSES IMPLEMENTED IN THE TREATMENT OF CATARACT UNDER DIFFERENT INSURANCE SCHEMES IN EGYPT

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PCN180 EQ-5D UTILITY ESTIMATES FROM THE IMPOWER 133 TRIAL OF TECENTRIQ + CARBOPLATIN + ETOPOSIDE VS. CARBOPLATIN + ETOPOSIDE IN FIRST LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)

    Nov 1, 2019, 00:00

  • PND9 UPDATED META-ANALYSIS OF THE EFFICACY OF ADJUVANT TREATMENT TO LEVODOPA IN PARKINSON'S DISEASE

    Nov 1, 2019, 00:00

  • PCN67 COST-EFFECTIVENESS ANALYSIS OF DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY IN PORTUGAL

    Nov 1, 2019, 00:00

  • PCN494 POTENTIAL USE OF ARTIFICIAL INTELLIGENCE TO ANALYZE DATA EXTRACTED FROM ELECTRONIC HEALTH RECORDS FOR DECISION ANALYTIC MODELS

    Nov 1, 2019, 00:00

  • PIH46 COST EFFECTIVENESS ANALYSIS FOR A MULTI-FACTORIAL INTERVENTION FOR ELDERLY INPATIENTS WITH DELIRIUM, UTILIZING REAL WORLD DATA

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PMU62 ASSESSING WHETHER PRODUCTS NEED TO BE COST-SAVING IN ORDER TO GAIN ACCELERATED ACCESS COLLABORATIVE RAPID UPTAKE STATUS IN NHS ENGLAND

    Nov 1, 2019, 00:00

  • PCN364 REIMBURSEMENT OF CAR-T CELL THERAPY IN THE UK, A STEP TOWARDS MORE PERSONALISED CANCER TREATMENT

    Nov 1, 2019, 00:00

  • PCN277 INTER-REGIONAL INEQUALITY IN ITALIAN HEALTHCARE DELIVERY AFFECTS CHOICE OF SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) FOR THE TREATMENT OF HORMONE-RECEPTOR-POSITIVE BREAST CANCER

    Nov 1, 2019, 00:00

  • PRO120 EVOLUTION OF OBCS NECESSARY TO ACTIVATE VALUE WITHIN STEM CELL RARE DISEASES

    Nov 1, 2019, 00:00

  • PNS112 PHARMACIST’S PRIVILEGE IN SAUDI ARABIA: PHARMACIST PRESCRIBING AND THERAPEUTIC INTERCHANGE

    Nov 1, 2019, 00:00

  • PCN458 ATTITUDE TOWARDS PARTICIPATION ON BREAST CANCER SCREENING AND THE ASSESSMENT OF INFLUENCING FACTORS AMONG 45-65 YEARS OLD WOMEN

    Nov 1, 2019, 00:00

  • PMH30 COST-UTILITY ANALYSIS OF VORTIOXETINE FOR THE TREATMENT OF MAJOR DEPRESSION DISORDERS IN CHINA

    Nov 1, 2019, 00:00

  • PMU45 PREVALENCE VS. TREATMENT COST: ANALYSIS OF DRUGS FOR RARE DISEASE IN ITALY

    Nov 1, 2019, 00:00

  • PIN86 CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH VARYING COVERAGE OF VARICELLA VACCINATION STRATEGIES IN SWITZERLAND

    Nov 1, 2019, 00:00

  • PNS250 CADTH PARALLEL SCIENTIFIC ADVICE PROGRAMS WITH NICE AND HEALTH CANADA

    Nov 1, 2019, 00:00

  • PUK35 THE BURDEN OF INCONTINENCE IN A REAL-WORLD DATA ENVIRONMENT - INSIGHTS FROM A DIGITAL PREVENTION COMPANION

    Nov 1, 2019, 00:00

  • Comparative Effectiveness or Efficacy Studies

    Nov 1, 2019, 00:00

  • PRO9 A SYSTEMATIC REVIEW OF THE CLINICAL BURDEN OF IDIOPATHIC MULTICENTRIC CASTLEMAN'S DISEASE

    Nov 1, 2019, 00:00

  • PCN434 THE EFFECT MODIFICATION PROBLEM: USING STRATIFIED MATCHING ADJUSTED INDIRECT COMPARISON TO EVADE MISLEADING INTERPRETATIONS OF THE TREATMENT EFFECT

    Nov 1, 2019, 00:00

  • PBI88 ASSESSMENT OF PATIENTS AFFECTED BY RHEUMATOID ARTHRITIS ELIGIBLE FOR BIOLOGIC AGENTS

    Nov 1, 2019, 00:00

  • PRO17 A BUDGET IMPACT ANALYSIS OF ANTI-INHIBITOR COAGULANT COMPLEX USE IN PEDIATRIC HEMOPHILIA A PATIENTS WITH INHIBITORS ACROSS KINGDOM OF SAUDI ARABIA.

    Nov 1, 2019, 00:00

  • PIN145 PATIENT PREFERENCES TOWARDS DRUG TREATMENT OF CHRONIC HEPATITIS B - A DISCRETE CHOICE EXPERIMENT IN GERMANY

    Nov 1, 2019, 00:00

  • PDB109 BURDEN OF ILLNESS ASSOCIATED WITH HYPERPHAGIA AND SEVERE OBESITY

    Nov 1, 2019, 00:00

  • PCN75 EPIDEMIOLOGY, MORTALITY AND STANDARD OF CARE IN ADVANCED BREAST CANCER - A MULTIPLE COUNTRY ANALYSIS

    Nov 1, 2019, 00:00

  • PCV27 AN ECONOMIC ANALYSIS OF ENDOVASCULAR ARTERIOVENOUS FISTULAS IN DIALYSIS PATIENTS: A U.S. PAYER AND PROVIDER PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN350 CLINICAL AND ECONOMIC ASSESSMENT OF THE IMPORTANCE OF SUPPORTIVE THERAPY IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PSU16 ESTIMATING THE CLINICAL AND ECONOMIC IMPACT OF IMPLEMENTING PREOPERATIVE ANEMIA MEASURES IN THE GERMAN HEALTHCARE SYSTEM: THE HEALTH ECONOMIC FOOTPRINT OF PATIENT BLOOD MANAGEMENT (PBM)

    Nov 1, 2019, 00:00

  • PCN173 ACCOUNTING FOR TIME-DEPENDENT HEALTH STATE MEMBERSHIP IN BUDGET IMPACT ANALYSIS - CASE STUDY IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PIN105 DESCRIPTION OF PATIENTS HOSPITALIZED WITH MENINGOCOCCAL INFECTIONS IN FRANCE: AN ANALYSIS OF THE NATIONAL HEALTHCARE CLAIM(SNIIR-AM) DATABASE

    Nov 1, 2019, 00:00

  • PR2 FATIGUE: ITS USE ACROSS TRIALS FOR MULTIPLE CONDITIONS: REGULATORY SUCCESS

    Nov 1, 2019, 00:00

  • PCN421 STABILITY OF LIFETIME OVERALL SURVIVAL ESTIMATES OF NIVOLUMAB+IPILIMUMAB IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA

    Nov 1, 2019, 00:00

  • PBI31 COST-EFFECTIVENESS COMPARISON OF RISANKIZUMAB AND USTEKINUMAB FOR THE TREATMENT OF SEVERE PSORIASIS

    Nov 1, 2019, 00:00

  • Alternative Medicine Statistical Research

    Nov 1, 2019, 00:00

  • PNS126 NEW DRUG BUDGET AND REIMBURSEMENT POLICY IN TAIWAN

    Nov 1, 2019, 00:00

  • PMS13 EXPERIMENTAL STUDY OF TOPICAL TREATMENT OF RHEUMATOID ARTHRITIS WITH TNF-Α ANTAGONIST

    Nov 1, 2019, 00:00

  • PGI37 REDUCTION IN CO-THERAPY COSTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH BIOLOGICAL DRUGS

    Nov 1, 2019, 00:00

  • PRS22 THE COST EFFECTIVENESS OF DORNASE ALFA VERSUS INHALED TOBRAMYCIN IN THE MANAGEMENT OF PATIENTS WITH CYSTIC FIBROSIS

    Nov 1, 2019, 00:00

  • PCN305 FUNDING TRENDS FOR IN-HOSPITAL DRUGS: GERMAN NUB ANALYSIS

    Nov 1, 2019, 00:00

  • PRO123 DEVELOPING AN EVIDENCE GENERATION PLAN FOR THE VALUE STORY OF AN ORPHAN DRUG

    Nov 1, 2019, 00:00

  • PMU39 CERVICAL CANCER PREVENTION THROUGH HUMAN PAPILLOMAVIRUS (HPV) VACCINATION: A CASE STUDY IN ETHIOPIA

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PCN22 BURDEN OF BRAIN METASTASES (BM) IN ALK+ NON-SMALL CELL LUNG CANCER (ALK+ NSCLC) TREATED WITH FIRST-LINE ALK INHIBITORS: RESULTS OF A SYSTEMATIC LITERATURE REVIEW (SLR)

    Nov 1, 2019, 00:00

  • PCN238 IS POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE-RITUXIMAB COST-EFFECTIVE FOR PATIENTS IN THE UNITED STATES WITH TRANSPLANT-INELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA?

    Nov 1, 2019, 00:00

  • PNS178 PRIVATE HEALTH INSURANCE PERCEPTION OF THEIR ROLE AFTERWARD UNIVERSAL HEALTH INSURANCE IN EGYPT

    Nov 1, 2019, 00:00

  • PSY54 WEB SURVEY AND FOCUS GROUPS EXPLORING KNOWLEDGE, NEEDS AND EXPECTATIONS AMONG SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: PRELIMINARY RESULTS

    Nov 1, 2019, 00:00

  • PCV86 ASSOCIATION OF ADHERENCE AND TREATMENT INTENSITY OF LIPID-LOWERING THERAPY WITH CARDIOVASCULAR OUTCOMES AND ALL-CAUSE MORTALITY IN POST-MI PATIENTS IN GERMANY.

    Nov 1, 2019, 00:00

  • PCN336 PARALLEL SCIENTIFIC ADVICE FROM NICE AND CADTH: WOULD ONE SUBMISSION FIT ALL?

    Nov 1, 2019, 00:00

  • PCN32 COMPARATIVE EFFICACY OF PEMBROLIZUMAB PLUS AXITINIB (P+A) VERSUS FIRST-LINE SYSTEMIC THERAPIES FOR ELDERLY PATIENTS WITH ADVANCED/METASTATIC RCC (MRCC): A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS

    Nov 1, 2019, 00:00

  • Surgery - Economic Evaluation

    Nov 1, 2019, 00:00

  • PDG14 COST-UTILITY OF DALBAVANCIN VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH ABSSSI IN ITALY

    Nov 1, 2019, 00:00

  • PSS20 CONFIRMATION OF THE MEASUREMENT PROPERTIES OF THE NATIONAL EYE INSTITUTE VISUAL FUNCTIONING QUESTIONNAIRE 28 ITEM RASCH-BASED SCORING IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

    Nov 1, 2019, 00:00

  • PCV54 THE HEALTHCARE MANAGEMENT OF PATIENTS WITH THE CORONARY AND PERIPHERAL ARTERIAL DISEASES

    Nov 1, 2019, 00:00

  • PMU152 SWITCHING AMONG BIOLOGIC THERAPIES IN PATIENTS WITH RHEUMATOID ARTHRITIS: A CROSS-SECTIONAL STUDY

    Nov 1, 2019, 00:00

  • PIN94 HUMAN PAPILLOMAVIRUS (HPV) VACCINE COVERAGE RATES (VCR) IN FRANCE: A FRENCH CLAIMS DATA STUDY

    Nov 1, 2019, 00:00

  • PCN480 RELEVANCE OF SELECTED PATIENT-REPORTED OUTCOME (PRO) MEASURES IN EPSTEIN-BARR VIRUS ASSOCIATED (EBV+) POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (PTLD) PATIENTS

    Nov 1, 2019, 00:00

  • PRS65 BEVACIZUMAB INDUCED PULMONARY EMBOLISM: A DISPROPORTIONALITY ANALYSIS IN USFDA ADVERSE EVENT REPORTING SYSTEM DATABASE

    Nov 1, 2019, 00:00

  • PCN118 DIRECT MEDICAL COSTS OF THE TREATMENT OF RECTAL CANCER: A REVIEW AND SYNTHESIS OF THE PUBLISHED EVIDENCE

    Nov 1, 2019, 00:00

  • PDB32 WOULD A COHORT-LEVEL APPROACH TO COST-EFFECTIVENESS MODELLING HAVE LED TO A DIFFERENT DECISION IN AN IMPORTANT NICE APPRAISAL FOR OBESITY PATIENTS?

    Nov 1, 2019, 00:00

  • PDB106 DOES MOBILE HEALTH LIVE UP TO EXPECTATIONS? EXPLORING REAL-WORLD EXPERIENCES IN PATIENTS WITH DIABETES

    Nov 1, 2019, 00:00

  • PCN499 REAL WORLD TREATMENT AND SURVIVAL OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: AN ANALYSIS USING JAPANESE CLAIMS DATA

    Nov 1, 2019, 00:00

  • PND133 IMPACT OF CLINICAL COMPLICATIONS ON ECONOMIC BURDEN IN NEWLY DIAGNOSED PARKINSON POPULATION USING A US CLAIM DATABASE

    Nov 1, 2019, 00:00

  • PND50 ECONOMIC BURDEN OF ALZHEIMER'S DISEASE DEMENTIA IN JAPAN

    Nov 1, 2019, 00:00

  • PCN47 REAL WORLD EVIDENCE OF DARATUMUMAB IN MULTIPLE MYELOMA

    Nov 1, 2019, 00:00

  • PCN78 CHANGES IN HEALTH STATE COSTS IN HEPATOCELLULAR CARCINOMA (HCC)

    Nov 1, 2019, 00:00

  • PNS97 GEOGRAPHIC DIFFERENCES IN IRISH HEALTH STATUS

    Nov 1, 2019, 00:00

  • PNS384 HEALTH-RELATED QUALITY OF LIFE (HRQOL) MEASURED BY PROMIS PREFERENCE SCORE (PROPR) IN THE GENERAL POPULATION OF THE UNITED KINGDOM, FRANCE, AND GERMANY

    Nov 1, 2019, 00:00

  • PMD8 ESTIMATING THE POTENTIAL CASES OF BLINDNESS AND COSTS AVOIDED AND IN REALLOCATING HEALTHCARE RESOURCE UTILIZATION FROM TREATING POSTERIOR CAPSULAR OPACIFICATION TO NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

    Nov 1, 2019, 00:00

  • PCV154 A NOVEL PREDICTION FOR ADVERSE CARDIAC EVENTS IN PATIENTS WITH NON-OBSTRUCTIVE CORONARY ARTERY DISEASE

    Nov 1, 2019, 00:00

  • PIN57 ECONOMIC EVALUATION OF AN ELECTRONIC HEALTH RECORD ALERT BY AGE IN PRIMARY CARE FOR THE DETECTION OF PATIENTS WITH CHRONIC HEPATITIS C

    Nov 1, 2019, 00:00

  • PNS197 WAITING TIMES FOR HEALTH CARE SERVICES IN HUNGARY - RESULTS OF A REPRESENTATIVE POPULATION SURVEY

    Nov 1, 2019, 00:00

  • PSU44 MANAGEMENT OF PERIPROCEDURAL THROMBOTIC AND BLEEDING EVENTS IN PERCUTANEOUS CORONARY INTERVENTIONS IN EUROPE: PILOT SURVEY OF TREATMENT STRATEGIES AND HOSPITAL RESOURCES USE

    Nov 1, 2019, 00:00

  • PIH11 ECONOMIC EVALUATION OF OSPEMIFENE FOR THE TREATMENT OF VULVOVAGINAL ATROPHY IN THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PCN281 IDENTIFYING THE KEY CHALLENGES IN EVALUATION AND PRICING OF ONCOLOGY COMBINATION THERAPIES AND FUTURE POLICY CHANGES USING A WEB-BASED PORTAL TO ENGAGE PAYERS

    Nov 1, 2019, 00:00

  • PRO26 THE NICE APPRAISAL OF BUROSUMAB FOR THE TREATMENT OF XLH: EVALUATING THE LIFELONG OUTCOMES AND COST-EFFECTIVENESS OF CORRECTING DEFORMITY WHEN TREATING CHILDREN AND ADOLESCENTS WITH A GROWING SKELETON

    Nov 1, 2019, 00:00

  • PRS67 GENDER DIFFERENCES IN ASTHMA PERCEPTION AND IMPACT ON QUALITY OF LIFE: A POST-HOC ANALYSIS OF THE PROXIMA OBSERVATIONAL STUDY

    Nov 1, 2019, 00:00

  • PMU131 VALIDITY OF THE POLISH VERSION OF THE CARERQOL-7D QUESTIONNAIRE AMONG INFORMAL CAREGIVERS IN THE POLISH GENERAL POPULATION

    Nov 1, 2019, 00:00

  • PCV105 A SCOPING REVIEW OF INTERNATIONAL MODELS OF ADULT SPECIALIST CARDIAC NETWORKS

    Nov 1, 2019, 00:00

  • PMU34 COMPARATIVE ANALYSIS OF DISABILITY ADJUSTED LIFE YEARS FROM ADVERSE EFFECTS OF MEDICAL TREATMENT IN UKRAINE AND OTHER COUNTRIES

    Nov 1, 2019, 00:00

  • PRO97 VALUE ASSESSMENT FRAMEWORKS FOR ORPHAN DRUGS: A COMPARATIVE ANALYSIS ACROSS EUROPEAN JURISDICTIONS

    Nov 1, 2019, 00:00

  • PBI26 THE ECONOMIC REASON FOR THE USE OF VEDOLIZUMAB COMPARED WITH INHIBITORS OF TNF-ALPHA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON THE EXAMPLE OF MOSCOW

    Nov 1, 2019, 00:00

  • PMS23 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE ANKLE AND FOOT IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PIT15 INTRAMEDULLARY NAILING OF HUMERAL FRACTURES: PATIENT CHARACTERISTICS ASSOCIATED WITH POSTOPERATIVE COMPLICATIONS

    Nov 1, 2019, 00:00

  • PMU84 DRUG DECISION-MAKING PATHWAYS IN ENGLAND: CURRENT PROCESSES AND THE POTENTIAL IMPACT OF NICE CHANGES

    Nov 1, 2019, 00:00

  • PNS316 USE OF GENERALISED FLUCTUATION TEST TO OPTIMISE PIECEWISE FITTING IN IMMUNO-ONCOLOGY (IO) SURVIVAL MODELLING

    Nov 1, 2019, 00:00

  • PNS336 NETWORK META-ANALYSIS (NMA) WITH TIME-VARYING HAZARD: A COMPARATIVE ANALYSIS OF SURVIVAL OUTCOMES

    Nov 1, 2019, 00:00

  • PNS143 PRIORITIZATION OF DRUGS FOR REIMBURSEMENT IN THE MALTESE HEALTH SYSTEM.

    Nov 1, 2019, 00:00

  • PMH64 PHARMACOTHERAPY COST AND PRESCRIBING PRACTICE FOR PSYCHOTIC DISORDERS IN BULGARIA

    Nov 1, 2019, 00:00

  • PMU108 LEVERAGING ELECTRONIC HEALTH RECORDS TO MEET THE REAL-WORLD EVIDENCE NEEDS OF HTA: A UK PERSPECTIVE

    Nov 1, 2019, 00:00

  • PUK10 BUDGET IMPACT ANALYSIS OF DEGARELIX FOR THE TREATMENT OF PROSTATE CANCER IN CHINA

    Nov 1, 2019, 00:00

  • PNS11 EARLY HEALTH ECONOMIC MODELLING AS A TOOL TO GUIDE STRATEGIC CLINICAL DEVELOPMENT AND IN-LICENSING DECISIONS

    Nov 1, 2019, 00:00

  • PNS3 COMPARISON OF FIVE METHODS FOR DOWNLOADING CONFERENCE ABSTRACTS: A CASE STUDY

    Nov 1, 2019, 00:00

  • PNS401 THE FIRST PARALLEL EQ-5D-3L AND EQ-5D-5L COMPOSITE TIME TRADE-OFF VALUATION STUDY IN EUROPE

    Nov 1, 2019, 00:00

  • PIN136 MODELLING CD4 TRANSITIONS IN HIV PATIENTS: VALIDATING A MARKOV MODEL BASED APPROACH

    Nov 1, 2019, 00:00

  • PCN278 EXPLORING PRE AND POST AGENZIA ITALIANA DEL FARMACO (AIFA) REIMBURSED ACCESS TO IMMUNOTHERAPY FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

    Nov 1, 2019, 00:00

  • PGI26 A BUDGET IMPACT ANALYSIS OF RIFAXIMIN FOR TREATMENT OF HEPATIC ENCEPHALOPATHY IN TERTIARY HOSPITAL,RIYADH, SAUDI ARABIA

    Nov 1, 2019, 00:00

  • RW2 METHODOLOGICAL APPROACHES FOR INCORPORATING REAL-WORLD DATA (RWD) FOR OVERALL SURVIVAL (OS) INTO LONG-TERM SURVIVAL ESTIMATES: A CASE-STUDY NICE TECHNOLOGY APPRAISAL IN EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (ES-SCLC)

    Nov 1, 2019, 00:00

  • PNS332 DEALING WITH MISSING DATA IN TRIAL-BASED ECONOMIC EVALUATIONS: A METHODOLOGICAL SCOPING REVIEW

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PMD60 AN INNOVATIVE REUSABLE ELECTRONIC INJECTION DEVICE FOR CERTOLIZUMAB PEGOL: RESULTS FROM A PILOT MARKET RESEARCH STUDY EXAMINING PATIENT PREFERENCE AND SATISFACTION

    Nov 1, 2019, 00:00

  • PMD13 COST-UTILITY ANALYSIS OF ISTENT INJECT IN MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA IN JAPAN

    Nov 1, 2019, 00:00

  • PDB129 PRIMARY AND SECONDARY HEALTHCARE RESOURCE USE AND ASSOCIATED COSTS IN PEOPLE WITH HEPATIC ENCEPHALOPATHY IN ENGLAND

    Nov 1, 2019, 00:00

  • PDG54 INTERNATIONAL COMPARISON OF ORPHAN DRUG POLICY EFFECT ON ORPHAN DRUG EXPENDITURE

    Nov 1, 2019, 00:00

  • PDG36 ANALYSIS OF GABAPENTINOIDS ABUSE IN THE MIDDLE EAST AND NORTH AFRICA REGION UTILIZING THE FOOD AND DRUG ADMINISTRATION ADVERSE EVENTS REPORTING SYSTEM DATABASE

    Nov 1, 2019, 00:00

  • PRO153 PSYCHOMETRIC VALIDATION OF THE PROMIS PHYSICAL FUNCTION MOBILITY, PAIN INTERFERENCE AND FATIGUE IN A COHORT OF PAEDIATRIC X-LINKED HYPOPHOSPHATEMIA (XLH) PATIENTS

    Nov 1, 2019, 00:00

  • PIN113 EU MARKET ACCESS PATHWAYS FOR VACCINES: DEFINITION OF COUNTRY ARCHETYPES USING MATHEMATICAL CLUSTERING

    Nov 1, 2019, 00:00

  • PCN423 MEASURING FATIGUE SYMPTOMS AND IMPACTS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): EVALUATING DIMENSIONALITY OF THE FACIT-FATIGUE

    Nov 1, 2019, 00:00

  • PCN407 SOMATOSTATIN ANALOGUES IN IMAGING OF BREAST CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2019, 00:00

  • PCN328 CHANGING EPIDEMIOLOGY AND TREATMENT ALGORITHM IN PANCREATIC CANCER IN GERMANY 2017-2018

    Nov 1, 2019, 00:00

  • PNS115 BARRIERS TO TRANSPARENCY IMPROVEMENT OF HOSPITALS PERFORMANCE: A QUALITATIVE STUDY IN IRAN

    Nov 1, 2019, 00:00

  • PMD3 RETROSPECTIVE ANALYSIS OF OXIDIZED ZIRCONIUM BEARING SURFACE IN HIP REPLACEMENT 90-DAY EPISODE CLAIMS

    Nov 1, 2019, 00:00

  • PCN340 FAST CHANGING APPROPRIATE COMPARATORS IN GERMAN AMNOG BENEFIT ASSESSMENTS IN MULTIPLE MYELOMA

    Nov 1, 2019, 00:00

  • PCN468 SYSTEMATIC REVIEW OF UTILITY ESTIMATES IN TRIPLE-NEGATIVE BREAST CANCER PATIENTS

    Nov 1, 2019, 00:00

  • PCN159 COST-UTILITY ANALYSIS OF TRIFLURIDINE/TIPIRACIL FOR HEAVILY PRETREATED METASTATIC GASTRIC CANCER IN JAPAN

    Nov 1, 2019, 00:00

  • PNS73 WHAT IS THE VALUE FOR A QALY IN FRANCE?

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PMS43 DUCHENNE MUSCULAR DYSTROPHY PREVALENCE IN FIVE EUROPEAN COUNTRIES: A NOVEL INCIDENCE-BASED MODELING APPROACH USING SYSTEM DYNAMICS

    Nov 1, 2019, 00:00

  • PMU128 MY DAUGHTER LOVES THE NEW PENS!: QUANTIFYING THE PATIENT EXPERIENCE WITH MACHINE READING AND APPLIED SEMANTIC COMPUTING

    Nov 1, 2019, 00:00

  • PNS289 EVALUATION OF THE SAFETY AND EFFICACY OF AI FOR DETECTION OF CHRONIC NON-COMMUNICABLE DISEASES IN REMOTE AREAS

    Nov 1, 2019, 00:00

  • PMS74 TAPERING BIOLOGIC? AN INSIGHT AND PERSPECTIVE OF RHEUMATOID ARTHRITIS PATIENTS

    Nov 1, 2019, 00:00

  • PCN60 VALUE OF NEOADJUVANT IO THERAPIES WITH OR WITHOUT ADJUVANT CANCER THERAPIES: A MODEL FRAMEWORK

    Nov 1, 2019, 00:00

  • PCN142 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN BELGIUM: ANALYSIS USING 48-MONTH OVERALL SURVIVAL FROM CHECKMATE 067

    Nov 1, 2019, 00:00

  • PCV21 TIMI RISK SCORE IN PREDICTING IN HOSPITAL AND EARLY MORTALITY AFTER PRIMARY PERCUTANEOUS CORONARY INTERVENTION IN ELDERLY WOMEN:RESULTS FROM A DEVELOPING COUNTRY

    Nov 1, 2019, 00:00

  • Infectious Diseases - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PNS319 USE OF ARTIFICIAL INTELLIGENCE WITH DISTILLERSR SOFTWARE AS A REVIEWER FOR A SYSTEMATIC LITERATURE REVIEW OF COST-EFFECTIVENESS MODELS

    Nov 1, 2019, 00:00

  • PMH16 LONG-TERM COST-EFFECTIVENESS OF ESKETAMINE FOR THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION

    Nov 1, 2019, 00:00

  • PCN412 COMPARING THE LONG-TERM SURVIVAL METHODOLOGIES IN PHARMACOECONOMIC MODELS OR GLIOBLASTOMA: WHICH BEST REFLECT REAL-WORLD OUTCOMES?

    Nov 1, 2019, 00:00

  • PMU137 A BIBLIOMETRIC ANALYSIS OF SOUTH AFRICAN HEALTH-RELATED QUALITY OF LIFE STUDIES RELEVANT TO ECONOMIC EVALUATIONS

    Nov 1, 2019, 00:00

  • PCN426 WHEN CROSS-OVER ISN'T CROSS OVER. STRATEGIES FOR HANDLING EFFECTIVE SUBSEQUENT THERAPIES IN ECONOMIC ANALYSIS OF ONCOLOGY TRIALS

    Nov 1, 2019, 00:00

  • PDB97 THE EFFECT OF NIGHT EATING ON NUTRITIONAL HABITS AND QUALITY OF LIFE OF DIABETIC PATIENTS

    Nov 1, 2019, 00:00

  • PSY16 COST-EFFECTIVENESS OF TOFACITINIB IN ACTIVE PSORIATIC ARTHRITIS AFTER CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS TREATMENT IN SPAIN

    Nov 1, 2019, 00:00

  • PMH66 COMPARISON OF HEALTHCARE RESOURCE UTILIZATION (HCRU) AND EXPENDITURES AMONG US COMMERCIALLY-INSURED PATIENTS WITH OPIOID USE DISORDER (OUD) BY TYPE OF MEDICATION-ASSISTED TREATMENT (MAT) RECEIVED

    Nov 1, 2019, 00:00

  • PDB124 BURDEN OF HEART FAILURE IN PATIENTS WITH DIABETES IN ENGLAND

    Nov 1, 2019, 00:00

  • PMS26 IMPACT OF CHRONIC LOW BACK PAIN ON EMPLOYMENT AND PRODUCTIVITY - RESULTS FROM A GLOBAL 8,990 PATIENT SURVEY: CITIZENS' RESEARCH

    Nov 1, 2019, 00:00

  • PCV87 A REVIEW ASSESSING THE PROPORTION OF HEART FAILURE WITH PRESERVED EJECTION FRACTION PATIENTS AMONGST HEART FAILURE PATIENTS

    Nov 1, 2019, 00:00

  • PIN114 UNDERSTANDING CHANGES IN FULL CHILDHOOD IMMUNIZATION COVERAGE IN ETHIOPIA BETWEEN 2000 AND 2016: OAXACA-BLINDER DECOMPOSITION ANALYSIS

    Nov 1, 2019, 00:00

  • PDB100 EXAMINING THE TEMPORAL TRENDS IN HYPOGLYCEMIA EVENTS, TREATMENT ADHERENCE AND A1C IN PATIENTS WITH T2D IN THE US

    Nov 1, 2019, 00:00

  • PBI6 WHAT IS THE APPROPRIATE DISCOUNT RATE IN ECONOMIC EVALUATIONS OF GENE THERAPIES (GT)?

    Nov 1, 2019, 00:00

  • PDB131 THE REAL-WORLD DOSE DIFFERENCES OF INSULIN GLARGINE 300 U/ML IN FINLAND

    Nov 1, 2019, 00:00

  • PCN236 A LANDMARK RESPONSE ANALYSIS TO DETERMINE COST-EFFECTIVENESS OF THIRD-LINE NIVOLUMAB MONOTHERAPY FOR SMALL CELL LUNG CANCER

    Nov 1, 2019, 00:00

  • PCN227 A PARTITIONED SURVIVAL MODEL TO DETERMINE COST-EFFECTIVENESS OF THIRD-LINE NIVOLUMAB MONOTHERAPY FOR SMALL CELL LUNG CANCER

    Nov 1, 2019, 00:00

  • PNS367 THE NATIONAL HEALTH COUNCIL PATIENT ENGAGEMENT RUBRIC: A GUIDE TO INCORPORATING THE PATIENT VOICE INTO THE HEALTHCARE ECOSYSTEM

    Nov 1, 2019, 00:00

  • PCN9 TREATMENT PATTERNS AND SURVIVAL IN UNRESECTABLE ADVANCED ESOPHAGEAL SQUAMOUS CELL CANCER IN THE SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) MEDICARE LINKED DATA

    Nov 1, 2019, 00:00

  • PCN269 INCIDENCE OF FECAL AND URINARY INCONTINENCE IN PATIENTS WITH A DIAGNOSIS OF RECTAL CARCINOMA

    Nov 1, 2019, 00:00

  • PDG47 STATUS QUO OF PHARMACEUTICAL CARE SYSTEM IN PRIMARY HEALTH CARE INSTITUTIONS OF CHINA——A LARGE SAMPLE SURVEY ON PRIMARY HEALTH CARE INSTITUTIONS OF JANGSU PROVINCE

    Nov 1, 2019, 00:00

  • PNS51 SHIFTING THE MARKET ACCESS FRAMEWORK TO INVESTMENT DECISIONS IN EARLY ASSETS

    Nov 1, 2019, 00:00

  • PRO128 AN EVIDENCE-BASED APPROACH TO PREDICT LONG-TERM PATIENT OUTCOMES IN PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME

    Nov 1, 2019, 00:00

  • PRO71 WHAT WAS THE ACTUAL BUDGET IMPACT OF ORPHAN MEDICINAL PRODUCTS BETWEEN 2000-2017 IN EUROPE?

    Nov 1, 2019, 00:00

  • PNS206 AIM FOR THE STARS, REACH THE MOON? A SIMPLE STRATEGY TO IMPROVE ADDITIONAL BENEFIT OUCTOMES IN GERMANY?

    Nov 1, 2019, 00:00

  • PNS274 CRITICALLY APPRAISING SYSTEMATIC REVIEWS OF ECONOMIC EVALUATIONS: WHAT, WHY AND HOW? AN EXPLORATORY STUDY USING AN IRISH NATIONAL CLINICAL GUIDELINE

    Nov 1, 2019, 00:00

  • PDB10 COST ASSOCIATED WITH UNCONTROLLED TYPE 2 DIABETES MELLITUS IN TWO TERTIARY HEALTHCARE FACILITIES IN A RESOURCE-LIMITED SETTING

    Nov 1, 2019, 00:00

  • PRO143 PSYCHOMETRIC EVALUATION OF THE ADVANCED SYSTEMIC MASTOCYTOSIS SYMPTOM ASSESSMENT FORM (ADVSM-SAF) IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS

    Nov 1, 2019, 00:00

  • PMS16 EFFECTS OF HYDROXYCHLOROQUINE ON THROMBOSIS FACTORS AND INFLAMMATORY CYTOKINES IN PATIENTS WITH ELDERLY RHEUMATOID ARTHRITIS

    Nov 1, 2019, 00:00

  • PCV134 MOBILE HEALTH TECHNOLOGY PERCEPTIONS AND USER EXPERIENCE AMONG ATRIAL FIBRILLATION PATIENTS: A SOCIAL MEDIA LISTENING STUDY

    Nov 1, 2019, 00:00

  • Neurological Disorders - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PRS25 THE IMPACT TRIAL: IS SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) COST-EFFECTIVE VERSUS DUAL THERAPY WITH INHALED CORTICOSTEROID PLUS LONG-ACTING BETA AGONIST (FF/VI) IN PATIENTS WITH COPD IN SPAIN?

    Nov 1, 2019, 00:00
  • «
  • 41 (current)
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • »